Polynucleotides for amplification and detection of sars-cov-2
AssigneeTalis Biomedical Corporation
InventorsNadya Andini, Kathy Chiu, Xuewen Jiang, Hédia Maamar
Life of this patent
Estimating the term…
Abstract
Disclosed herein are primers and probes related to the detection of SARS-CoV-2 via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of SARS-CoV-2 in test samples and/or to diagnose Covid-19. Specifically, the present disclosure describes primers and probes that bind to the N gene, ORF1ab, or E gene of SARS-CoV-2 coronavirus for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.
Claims29
-30. (canceled)
A composition comprising SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 51, SEQ ID NO:
- 52, SEQ ID NO:
- 53, and SEQ ID NO:
- 54.
A composition comprising a set of polynucleotides selected from the group consisting of:
- Set-5 and Set-9.
A method of detecting SARS-CoV-2 in a test sample, the method comprising:
- (a) extracting nucleic acid from the test sample;
- (b) amplifying a target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand displacement DNA polymerase activity, a reverse transcriptase activity, and a sequence-specific primer set, wherein said sequence-specific primer set is selected from the group consisting of:
- Set-5 and Set-9;
- and
- (c) detecting the presence or absence of an amplification product from step (b);
- wherein the presence of said amplification product is indicative of the presence of SARS-CoV-2 in the test sample.
Dependencies are inferred from the claim text.